- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
7/28/15 7:00 am EDT
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2015 and announced increases to the midpoints of its 2015 financial guidance(3) ranges for reported revenues(1) and reported(1) and adjusted(2) diluted EPS. The company manages its commercial operations through two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business is composed of two operatingmore...
- Second-Quarter 2015 Reported Revenues(1) of $11.9 Billion
- Second-Quarter 2015 Adjusted Diluted EPS(2) of $0.56, Reported Diluted EPS(1) of $0.42
- Raised Midpoints of 2015 Financial Guidance(3) Ranges for Reported Revenues(1) by $500 Million and Reported(1) and Adjusted(2) Diluted EPS by $0.03 and $0.04, Respectively, Due to Strong Performance to Date and Improved Business Outlook
- Second-Quarter 2015 Reported Revenues(1) for the Innovative Products Business Grew 17% Operationally, Primarily Driven by U.S. Launches of Prevnar 13 Adult and Ibrance
Pfizer Announces Expansion of Lease Agreement with Massachusetts Institute of Technology Subsidiary for Kendall Square Research Facility7/22/15 8:30 am EDT
Consolidation of Cambridge Research Centers Creates a Single Pfizer Cambridge Campus to Help Expedite Discovery and Development Efforts and Encourage Creative CollaborationNEW YORK--(BUSINESS WIRE)--Pfizer announced today the expansion of its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus in Kendall Square (KSQ). With this expansion, Pfizer has leased the full 500,000 square feet at 610 Main Street in Kendall Square. This space will continue to house the R&D activities that relocated to 610 Main Street in 2014, and will enable the consolidation of Pfizer’s three other leasedmore...
Pfizer’s Centers For Therapeutic Innovation And Jeffrey Modell Foundation Announce Collaboration to Help Advance Immunological Research7/8/15 8:30 am EDT
New Collaboration Aligns with Pfizer’s Commitment to Immunology and Rare Disease Drug DiscoveryNEW YORK--(BUSINESS WIRE)--Pfizer’s Centers for Therapeutic Innovation (CTI) and the Jeffrey Modell Foundation (JMF) announced today a collaboration agreement to conduct research in the field of immunological diseases. CTI and JMF will identify and co-fund translational research projects with leading academic medical centers within the CTI network. The goal of each research project will be to identify and validate a potential drug candidate for an immunological diseasemore...
Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery7/7/15 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery. The purpose of the study, named STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy), is to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperativemore...
Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate) Modified Release Tablets7/2/15 4:30 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) accepted for review Pfizer’s new drug application (NDA) for XELJANZ® (tofacitinib citrate) 11 mg once daily modified release tablets for the treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX). The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA)more...
6/25/15 11:20 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the election of Joseph J. Echevarria to its Board of Directors, effective immediately. Mr. Echevarria also was appointed to the Audit, Regulatory and Compliance and Science and Technology Committees of Pfizer’s Board. Mr. Echevarria, 58, retired as Chief Executive Officer (CEO) of Deloitte LLP, a global provider of professional services, in August 2014. He had been with the firm for 36 years and served inmore...
6/25/15 11:15 am EDTNEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 28-cent third-quarter 2015 dividend on the company’s common stock, payable September 2, 2015, to shareholders of record at the close of business on August 7, 2015. The third-quarter 2015 cash dividend will be the 307th consecutive quarterly dividend paid by Pfizer. About Pfizer Inc. At Pfizer, we apply science and our global resources to bring therapies to peoplemore...
CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA® for Adolescents and Young Adults 16 through 23 Years of Age6/24/15 1:19 pm EDT
Committee’s Recommendation Allows for Individual Clinical DecisionNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with healthcare providers. Specifically, the ACIP voted that a serogroup B meningococcal (MenB) vaccinemore...
6/23/15 2:00 pm EDT
RESET Trial to Assess Effectiveness and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Individuals with Sickle Cell DiseaseNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study – a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are six years of age or older. Sickle cell disease is one of the most prevalent genetic disorders inmore...
Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder6/11/15 3:00 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced the top line results from a Phase 3 study which evaluated the efficacy, safety, and tolerability of Pristiq® (desvenlafaxine succinate sustained-release formulation) in pediatric patients ages 7 to 17 with Major Depressive Disorder (MDD). The study did not meet its primary objective to demonstrate superior efficacy of desvenlafaxine succinate sustained-release formulation compared to placebomore...